Targeting a diverse spectrum of cancers.

Kinase switch control inhibitors for tumor-targeted and immune-targeted cancer therapies.

Platform

Deciphera’s proprietary switch control platform has generated a diverse clinical pipeline of kinase inhibitor drug candidates including tumor-targeted therapies and immuno-targeted therapies.

Investors

DCPH

$16.54

-0.21
12/15/17 4:00 PM EDT
© Nasdaq. Minimum 15 minutes delayed.

Latest News

Nov
28
2017
Deciphera Pharmaceuticals, Inc. Announces Orphan Drug Designation from the EMA for DCC-2618 for the Treatment of Gastrointestinal Stromal Tumors Read More »
Nov
21
2017
Deciphera Pharmaceuticals, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference Read More »
Nov
20
2017
Deciphera Pharmaceuticals Reports Data from Ongoing Phase 1 Clinical Study of DCC-2618¬†at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology Read More »